Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HRQOL in Patients with Cutaneous T-Cell Lymphoma

Int J Dermatol; ePub 2018 Aug 3; Holahan, Farah, et al

Health-related quality of life (HRQOL) in cutaneous T-cell lymphoma (CTCL) appears related to a number of factors, including presence of a psychiatric condition, use of systemic (particularly high grade) therapy, number of medical comorbidities, and income. This according to a recent study that aimed to establish baseline HRQOL data for patients with CTCL and identify its influencing factors. A prospective, nonblinded survey was conducted, utilizing questionnaires including panels of QOL indices obtained from 105 patients with mycosis fungoides, Sezary syndrome, and CD30+ lymphoproliferative disorder. Chart review correlated QOL with year of disease onset/diagnosis, type/stage of disease, current/past therapies, and medical/psychiatric diagnoses. Researchers found:

  • Psychiatric condition was significantly associated with symptoms, emotions, and functioning subscales along with overall composite measure.
  • High‐grade systemic therapy (OR=5.28) showed greater increase in odds of a lower health state than low grade (OR=1.54).
  • The number of medical comorbidities was significantly related to itching.
  • Increased age was a protective factor with respect to the emotions, functioning, and overall composite, but not predictive of symptoms.
  • Lower income was associated with higher bother on the symptoms subscale.

Holahan HM, Farah RS, Fitz S, et al. Health‐related quality of life in patients with cutaneous T‐cell lymphoma? [Published online ahead of print August 3, 2018]. Int J Dermatol. doi:10.1111/ijd.14132.